Option Care Health (NASDAQ:OPCH) Shares Gap Up – Should You Buy?

Option Care Health, Inc. (NASDAQ:OPCH) shares gapped up prior to trading on Thursday . The stock had previously closed at $29.31, but opened at $30.43. Option Care Health shares last traded at $30.01, with a volume of 177,273 shares changing hands.

Analysts Set New Price Targets

Several analysts have recently commented on OPCH shares. UBS Group assumed coverage on shares of Option Care Health in a research report on Thursday, December 5th. They set a “neutral” rating and a $26.00 price objective for the company. Truist Financial lowered their price objective on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 1st. JMP Securities restated a “market outperform” rating and set a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a report on Friday, January 10th. The Goldman Sachs Group downgraded shares of Option Care Health from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $38.00 to $27.00 in a report on Monday, November 4th. Finally, Jefferies Financial Group upgraded Option Care Health from a “hold” rating to a “buy” rating and raised their target price for the company from $26.00 to $35.00 in a report on Thursday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.14.

Option Care Health Stock Performance

The company’s 50-day moving average price is $24.10 and its two-hundred day moving average price is $27.78. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. The stock has a market cap of $5.07 billion, a PE ratio of 25.06, a PEG ratio of 2.12 and a beta of 1.31.

Insider Buying and Selling

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 43,000 shares of the business’s stock in a transaction on Friday, November 8th. The stock was acquired at an average cost of $22.54 per share, for a total transaction of $969,220.00. Following the completion of the transaction, the director now directly owns 326,334 shares in the company, valued at approximately $7,355,568.36. This represents a 15.18 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. UMB Bank n.a. raised its holdings in Option Care Health by 937.5% in the 3rd quarter. UMB Bank n.a. now owns 830 shares of the company’s stock worth $26,000 after purchasing an additional 750 shares in the last quarter. GAMMA Investing LLC raised its holdings in Option Care Health by 110.6% in the 3rd quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock worth $28,000 after purchasing an additional 471 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in Option Care Health by 3,362.8% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 1,489 shares of the company’s stock worth $47,000 after purchasing an additional 1,446 shares in the last quarter. International Assets Investment Management LLC lifted its stake in shares of Option Care Health by 3,029.7% in the 3rd quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock valued at $91,000 after purchasing an additional 2,757 shares during the period. Finally, Quarry LP lifted its stake in shares of Option Care Health by 327.7% in the 3rd quarter. Quarry LP now owns 3,430 shares of the company’s stock valued at $107,000 after purchasing an additional 2,628 shares during the period. Hedge funds and other institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.